Precithera was a private biopharmaceutical company created by CTI and based in Montreal, Canada. The company specialized in the development of precision medicines for rare bone diseases by combining computational technology with a deep understanding of disease pathology. PreciThera addressed heterogeneous genetic disorders that primarily manifest in bone dysfunction.
Rare bone disease
CTI LSF II
Co-Lead
Director
August 17, 2028
Liquidated in 2023
Seed
Precithera was created based on Dr. Philippe Crine, founder of Enobia, expertise in bone diseases and designing antibodies against intracellular peptides
